TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
TriSalus Life Sciences, a Nasdaq-listed oncology company, appointed Liselotte Hyveled to its Board of Directors. Hyveled, an industry veteran with over two decades of experience in pharmaceutical research and development, will contribute to TriSalus' vision of pioneering innovative treatments for liver and pancreatic cancers. Her strategic insights and patient-centric approach will be important in shaping the company's growth trajectory and advancing its technology and therapeutic pipelines.
TriSalus Life Sciences, a Nasdaq-listed oncology company, will host a conference call on May 15, 2024, at 9:00 a.m. ET to discuss first-quarter financial results and provide a business update. The call will cover the period ending March 31, 2024, and will be webcast live on their investor relations website.
TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.